ClinicalTrials.gg

Program

S-892216

A development code. Also written as “S-892216-PO” and “S-892216-LAI”.

Its studies are mostly in COVID-19 · Renal Insufficiency, led by Shionogi.

Furthest: phase 2, since Apr 9, 20254 company-led studies, 1 open or runningNext primary completion: Jun 30, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shionogi41 open or runningphase 2since Apr 9, 2025Dec 20, 2024Jun 30, 2028phase 1 · NCT07093580

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 20, 2024First study: phase 1 study in COVID-19First studyNCT06751017 · 16 enrolled · United States
  2. Apr 9, 2025Phase 2 study in COVID-19NCT06928051 · 282 enrolled · United States, Japan
  3. Jul 23, 2025Phase 1 study in COVID-19NCT07093580 · 128 planned · United States
  4. Oct 14, 2025Phase 1 study in Renal InsufficiencyNCT07217886 · 24 enrolled · United States

Ahead

  1. Jun 30, 2028Primary completion: phase 1 study in COVID-19NCT07093580

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07217886Renal Insufficiency · United States1CompletedFeb 13, 202624
NCT07093580COVID-19 · United States1RecruitingJun 30, 2028128
NCT06928051COVID-19 · United States, Japan2CompletedSep 22, 2025282
NCT06751017COVID-19 · United States1CompletedFeb 24, 202516

How it is read

Names in the registry

  • “S-892216”, 2 entries
  • “S-892216-PO”, 1 entry
  • “S-892216-LAI”, 1 entry

Codes read as this program: S892216.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.